RE:RE:RE:RE:one egg is being rolled out to the launch pad RF, I have to agree with Felco on this. If there isn’t at least $100M+ upfront, even more $$ in terms of development costs for clinical trials and much much more $$$$ in milestone payments then PLI will not be able to break the cash crisis cycle it is in and the shorts will continue to rule the day. So I can see lower royalty rates to achieve higher cash upfront in any future deal. these kind of numbers are fully warranted given that 4050 is a potential future standard of care drug for IPF.